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The 15th St. Gallen International Breast Cancer Conference 2017 in Vienna, Austria 
reviewed substantial new evidence on loco-regional and systemic therapies for early 
breast cancer. Treatments were assessed in light of their intensity, duration and side 
effects, seeking where appropriate to escalate or de-escalate therapies based on likely 
benefits as predicted by tumor stage and tumor biology. The Panel favored several 
interventions which may reduce surgical morbidity, including acceptance of 2 mm 
margins for DCIS, the resection of residual cancer (but not baseline extent of cancer) in 
women undergoing neoadjuvant therapy, acceptance of sentinel node biopsy following 
neoadjuvant treatment for many patients, and the preference for neoadjuvant therapy in 
HER2 positive and triple-negative, stage II and III breast cancer. The Panel favored 
escalating radiation therapy with regional nodal irradiation in high risk patients, while 
encouraging omission of boost in low risk patients. The Panel endorsed gene expression 
signatures that permit avoidance of chemotherapy in many patients with ER positive 
breast cancer. For women with higher risk tumors, the Panel escalated recommendations 
for adjuvant endocrine treatment to include ovarian suppression in premenopausal 
women, and extended therapy for postmenopausal women. However, low risk patients 
can avoid these treatments. Finally, the Panel recommended bisphosphonate use in 
postmenopausal women to prevent breast cancer recurrence. The Panel recognized that 
recommendations are not intended for all patients, but rather to address the clinical 
needs of the majority of common presentations. Individualization of adjuvant therapy 
means adjusting to the tumor characteristics, patient comorbidities and preferences, and 
managing constraints of treatment cost and access that may affect care in both the 








The fifteenth St. Gallen International Breast Cancer Consensus Conference was held in 
March 2017 in Vienna, Austria. This meeting is a global, multidisciplinary conference with 
representatives from 160 nations and every continent. The highlight of the conference is 
the consensus panel, in which 52 panelists review and discuss specific areas of treatment 
with a focus on controversies in the management of early stage breast cancer. The goal 
of this consensus process is to articulate important themes in management, and to 
provide guidance to clinicians around the world on how to think about and care for 
women with early stage breast cancer. It is acknowledged that not all countries have 
equal access to therapeutic and diagnostic resources. In light of that, the Panel attempts 
to review less costly alternatives when they may be appropriately utilized (Table 1).  
The theme for this year’s conference was to focus on areas of “escalation” or “de-
escalation.”  That is – to identify areas where optimal care may be achieved with “less” or 
“more” treatment. The Panelists believe very strongly in the importance of evidence-
based clinical care. At the same time, they recognize that data from randomized phase III 
studies are not always relevant to specific situations and may not be available to resolve 
important clinical decisions. The needs of a specific patient may be better defined through 
consideration of subset analyses or other individualized approaches to care. In these 
instances, the Panel voiced its expert judgment in order to assist in the care of individual 
women as best they could. The panel endorses treatment in well-designed clinical trials 
allowing access to best available care. 
 
 
Ductal Carcinoma in Situ 
 
Breast conserving surgery followed by radiation therapy remains the standard of care for 
ductal carcinoma in situ (DCIS) [1,2] assuming adequate margins can be obtained. The 
majority of panel endorsed recent Surgical Society of Oncology (SSO), American Society 
of Clinical Oncology (ASCO) and American Society for Radiation Oncology (ASTRO) 
guidelines that recommended that a margin ≥ 2 mm is sufficient to avoid re-excision [3]. 
A substantial minority of the panel would accept narrower margins in individual cases, 
including “no ink on DCIS.”  The Panel acknowledged the recent trials showing that either 
aromatase inhibitors (AIs) or tamoxifen can be an effective adjuvant treatment option to 
lower the risk of recurrent DCIS [4, 5]. 
 
Primary Surgery for Early Breast Cancer 
 
The panel discussed whether women with multifocal (multiple areas of tumor in one 
quadrant) or multicentric (multiple areas of tumor affecting more than one quadrant) are 
candidates for breast conservation. The Panel strongly endorsed breast conservation for 
both multifocal and multicentric disease provided that surgical margins are negative, that 
radiotherapy is anticipated, and that the surgical resection would afford adequate 
cosmesis. The Panel reiterated the “no ink on tumor” rule for surgical margins for invasive 
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breast cancer, and recommended this standard regardless of tumor biology or subtype 
[6]. 
A meta-analysis of single-center experiences suggests very low risk of local-regional 
recurrence following nipple-sparing mastectomy [7].  Based on these observations, the 
Panel endorsed nipple-sparing mastectomy as an appropriate surgical option. 
Additionally, the Panel specifically endorsed nipple-sparing mastectomy as an option for 
breast surgery in women with known hereditary BRCA1/2 mutations provided that there 
was careful review of the retro-areolar tissue by pathology with no evidence for tumor in 
that region. 
Based on the American College of Surgeons Oncology Group (ACOSOG) Z-11 trial, it has 
become standard to avoid axillary dissection in women with 1 or 2 positive sentinel lymph 
nodes who have had breast conservation and will be receiving whole breast radiation and 
adjuvant systemic therapy, regardless of tumor biology [8]. The Panel believed that either 
standard “tangents” or “high tangents” were appropriate radiation fields for such cases, 
and had no specific preference. 
The Panel discussed how this experience relates to women who have had mastectomy. 
The Panel recommended additional therapy to the axilla in women who had had 
mastectomy and sentinel node dissection with macrometastases affecting 1 or 2 lymph 
nodes. The Panel believed that either postsurgical radiation therapy or axillary dissection 
would be appropriate for such patients.  
 
Breast Surgery Following Neoadjuvant Therapy 
 
Neoadjuvant therapy serves two main goals. It provides effective systemic treatment 
(equivalent to adjuvant therapy) to prevent cancer recurrence, and affords a de-
escalation of surgery for many women with larger tumors and/or axillary nodal 
involvement. The Panel addressed the question: “Should the entire area of the original 
primary be resected after neoadjuvant therapy or should the resection include only the 
residual area of tumor?”, and the panel deliberated the appropriate surgical margins 
following neoadjuvant treatment [9]. The Panel recommended that the extent of residual 
tumor guide the extent of breast surgery, and that full resection of the initial tumor bed 
was not necessary. In general, the Panel favored the “no ink on tumor” standard for 
surgical margins following neoadjuvant therapy. However, in cases of multifocal residual 
disease and/or cases of “scattered” residual disease, many panelists expressed an expert 
opinion to favor more “generous” margins. No single standard of care exists and the 
multidisciplinary team caring for the patient needs to exercise appropriate clinical 
judgment.  Similarly, the Panel agreed that nipple-sparing mastectomy was an option for 
patients following neoadjuvant treatment provided the retro-areolar region lacked tumor 
involvement [10]. 
 
Axillary Surgery Following Neoadjuvant Therapy 
 
The Panel deliberated on appropriate axillary surgery following neoadjuvant 
chemotherapy. In a woman who presented with a clinically negative axilla and who 
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received neoadjuvant treatment, the Panel strongly believed sentinel node dissection to 
be appropriate and favored sentinel dissection after neoadjuvant treatment.  
There was more controversy regarding sentinel node surgery for women who presented 
with a clinically positive axilla, and had a clinical response with down staging to a clinically 
negative axilla. The Panel believed sentinel node dissection, as opposed to axillary 
dissection, to be adequate if at least 3 or more negative sentinel nodes were detected 
and examined [11-14]. Because of concerns for false-negative results with limited 
sampling, sentinel node surgery was generally considered not adequate if only 1 or 2 
negative sentinel nodes were identified. The Panel recommended that patients with a 
clinically positive axilla or with macro-metastases identified in sentinel nodes after 
neoadjuvant therapy undergo completion axillary dissection [15]. The Panel was split on 
whether residual micro-metastatic lymph node involvement warranted completion 
dissection after neo-adjuvant therapy.  
 
Radiation Therapy after Breast Surgery 
 
Because of high levels of evidence for safety and long-term efficacy, the Panel believed 
that hypo-fractionated treatment was an appropriate standard for the majority of 
patients, particularly those over age 50, and that this represented an opportunity for 
treatment de-escalation [16]. The Panel also recognized partial breast irradiation as an 
option for women meeting the low-risk criteria put forward by the ASTRO / European 
Society for Radiotherapy and Oncology (ESTRO) guideline though acknowledged that 
there was less evidence for this approach [17]. For women with intermediate or higher 
clinical risk, the Panel preferred whole breast irradiation. In another instance of de-
escalation, the Panel believed that “boost” could be omitted in patients aged ≥ 60, with 
low grade tumor features and/or favorable tumor biology who will be taking adjuvant 
endocrine therapy [18, 19]. 
Two recent randomized trials have shown improved oncological outcomes for regional 
nodal irradiation (RNI) for women with node positive and high risk node negative  breast 
cancers [20, 21]. The Panel recommended RNI in patients with pN1 (1 to 3 positive nodes) 
cancers and adverse clinical features including young age (≤ 40 years), adverse biology 
such as low or negative estrogen receptor (ER) expression, high grade features, and 
extensive lympho-vascular invasion (LVI), and  all patients with 4 or more positive lymph 
nodes. For women pN1 with lower risk features the potential benefits of RNI should 
be weighed against risks for toxicity, including pneumonitis and lymphedema.   
The Panel recommended post-mastectomy radiation therapy (PMRT) in all patients with 
4 or more positive lymph nodes and/or pT3 tumors. For women with pT1/pT2 pN1 
cancers, the Panel recommended PMRT when adverse clinical factors (above) were 
present. For pN1 with lower risk features the use of PMRT should be weighed against 
risks for toxicity, including increased of complications following breast 
reconstruction.   
 
Table 2 summarizes treatment recommendations for loco-regional therapies. 
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The Panel acknowledged the limited data for tailored radiation therapy based on 
neoadjuvant treatment response, and recommended that both baseline and post-
treatment cancer stage be considered in planning whether and how to administer 
radiation therapy. Finally, in the sentinel node-era, it is likely that radiation treatment 
decisions will need to be made with less complete staging information. Ongoing clinical 
trials including the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-51 and 
Alliance A11202 studies will inform this decision. 
 
Characterization of Tumor Biology, Subtypes and Genomic Signatures 
 
The St. Gallen Consensus has for years led in the development of treatment tailored 
towards clinical and biological subsets of breast cancer. In broad clinical terms, there are 
four subtypes of breast cancer that call for distinct treatment approaches:  triple-negative 
tumors, for which chemotherapy is both effective and the only available therapy; HER2 
positive tumors regardless of ER status, for which anti-HER2 therapy and chemotherapy 
are indicated; and two types of ER positive breast cancer, both of which are treated with 
endocrine therapy.  For many of these patients with hormone receptor positive disease, 
chemotherapy can be omitted. ER and Progesterone Receptor (PR) status is determined 
by immunohistochemistry (IHC); human epidermal growth factor receptor (HER2) status 
is determined by IHC and/or Fluorescence in situ hybridization (FISH) status. In addition, 
tumors are characterized by grade and proliferation, factors that may affect the 
recommendation for chemotherapy in ER positive tumors (Table 3). The Panel 
recommended against routine reporting of tumor infiltrating lymphocytes for early breast 
cancer. 
As a clinical “short-hand,” tumors are often classified as “luminal-A like” or “luminal-B 
like” based on routine pathology. Luminal A-like tumors are typically low grade, strongly 
ER / PR positive, HER2 negative and have low proliferation scores. Luminal-B-like tumors 
are ER positive but may have variable degrees of ER/PR expression, are higher grade, and 
have higher rates of proliferation. The Panel acknowledged that these classifications 
based on routine histopathology were clinically valuable, and could be used to influence 
adjuvant treatment decisions. Specifically, the panel agreed that either grading or Ki-67 
could be used to distinguish between the Luminal –A-like and B-like (Table 3).  
However, the panel agreed that, when available, gene expression signatures were 
preferable to standard pathology, when adequate reproducibility is not ascertained. 
There was considerable discussion concerning the indication for gene expression 
signatures [22]. The panel agreed that there was no role in clinical low risk cases [such as 
pT1a/b, grade 1 (G1), ER high, N0] and similar settings where chemotherapy would not 
be indicated under any circumstances. The Panel agreed that a number of gene 
expression signatures served as prognostic markers in the setting of adjuvant endocrine 
therapy in node-negative breast cancers, including the 21 gene recurrence score, the 70 
gene signature, the PAM50 ROR score ®, the EpClin score ® and the Breast Cancer Index 
®. The Panel endorsed all of these assays for guiding the decision on adjuvant 
chemotherapy in node-negative tumors as they all identify node-negative cases at low 
risk, with an excellent prognosis that would not warrant chemotherapy   [23-27] 
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Nodal status is a strong prognostic factor regardless of gene expression signature. The 
Panel agreed that gene expression signatures offered information that can refine the 
prognosis for node-positive breast cancers. However, the Panel did not uniformly endorse 
the use of gene expression signatures for making treatment decisions regarding adjuvant 
chemotherapy in node-positive cases. The 21-gene recurrence score and the 70 gene 
signature have now been evaluated in prospective studies including small numbers of 
node-positive cancers.  In the prospective trial (MINDACT), only patients with node-
negative, or 1-3 positive nodes were included. Patients with low risk tumor scores and a 
limited degree of nodal involvement appear to have a good prognosis with or without 
chemotherapy [28]. 
The Panel reviewed similar data showing that some gene expression signatures appear to 
be prognostic for late recurrence of ER positive breast cancers after 5 years of adjuvant 
endocrine therapy [29-31]. However, the Panel did not recommend the use of gene 
expression signatures for choosing whether to recommend extended adjuvant endocrine 
treatment, as no prospective data exist and the retrospective data were not considered 
sufficient to justify the routine use of genomic assays in this setting.  
The Panel discussed the routine indications for multigene testing in ER positive breast 
cancer. The principal role is to recommend for or against adjuvant chemotherapy. In 
patients who are not candidates for adjuvant chemotherapy owing to comorbid health 
conditions or tumor stage/risk, or in patients who “obviously” need adjuvant 
chemotherapy, typically including stage III breast cancer, there is no routine need for 
genomic tests. In general, the zone “in between” is where genomic assays may be most 
valuable. These would often be patients with tumors between 1 and 3 cm, with zero to 
2/3 positive lymph nodes, and intermediate proliferation scores. Multigene assay should, 
not be the only factor considered in making a decision to proceed or to avoid 
chemotherapy.  This broad description is intended to give guidance to clinicians and was 
not intended to deny access of patients with other clinical presentation where the refined 
prognosis available by genomic assay might reasonably inform the adjuvant 
chemotherapy decision.  
 
Adjuvant Endocrine Therapy: Premenopausal Women 
 
Tamoxifen is the historical standard adjuvant endocrine therapy for premenopausal 
women. The Panel reviewed data from recent trials of adjuvant ovarian function 
suppression that demonstrated that ovarian function suppression (OFS) can lower the risk 
of breast cancer recurrence in higher risk cancers [32]. The Panel identified age ≤ 35 
and/or involvement of 4 or more lymph nodes as factors arguing for inclusion of ovarian 
function suppression. In general, based on published reports, women with sufficient 
tumor risk so as to warrant chemotherapy may wish to consider OFS. The Panel believed 
OFS could be paired with either tamoxifen or an AI (Table 4)  [33, 34]. Chemotherapy may 
cause transient or permanent menopause in younger women. The Panel urged caution 
when interpreting laboratory assays of pituitary - ovarian function such as estradiol, 
follicle stimulating hormone (FSH), or luteinizing hormone (LH) levels in women treated 
with chemotherapy, and encouraged use of gonadotropin releasing hormone (GnRH) 
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agonist therapy to achieve OFS when there was any clinical ambiguity regarding 




Adjuvant Endocrine Therapy: Postmenopausal Women 
 
A vast literature supports the use of tamoxifen or aromatase inhibitors in the adjuvant 
treatment of postmenopausal women. Large randomized trials have shown that initial 
treatment with aromatase inhibitors may reduce recurrence risk and improve survival 
compared to tamoxifen alone. The Panel noted that tamoxifen alone is still appropriate 
for some patients.  Slightly more than half of the panelists believed that an aromatase 
inhibitor should be used at some point during the course of adjuvant therapy.  Factors 
that favored the use of an aromatase inhibitor include node positivity, high Ki67, high 
grade, lobular histology, and HER2 positivity.  In women at high risk of recurrence, the 
panel favored the use of an aromatase inhibitor as initial therapy. The panel acknowledge 
the importance of patient preference and tolerability of therapy, particularly given the 
modest differences between tamoxifen and aromatase inhibitors even in somewhat high 
risk patients (Table 4) [36, 37]. 
Over the past decade, multiple trials have examined the role of extended adjuvant 
endocrine therapy beyond 5 years of treatment. Options include extended tamoxifen to 
10 years, extended AI therapy to 10 years, or five years of tamoxifen and then switching 
to an AI. The benefits of extended therapy include reductions in risk of local-regional and 
distant recurrence and in contralateral breast cancer. The Panel deliberated on which 
women should receive longer durations of therapy. In general, the Panel recommended 
longer durations in women with moderate to high risk of recurrence, typically defined as 
stage II or III breast cancers. In women with stage I cancers, the panel favored only 5 years 
of treatment (Table 4). Based on data from recently presented studies, the Panel was 
more inclined to recommend extended therapy in women who had received tamoxifen 
as initial therapy, and in women where secondary prevention was an important treatment 
goal  [38-41]. The Panel underscored the importance of patient preference and tolerability 
in this treatment decision, as extended therapy is associated with ongoing menopausal 
symptoms and risks to bone health, and yield only modest benefits in terms of preventing 
breast cancer recurrence, especially in those who have completed 5 years of AI therapy 
(Table 4). 
The Panel recommended that premenopausal women who are at high risk for recurrence 
and have concluded 5 years of tamoxifen should extend endocrine therapy for up to 10 
years (Table 4) [42]. 
 
Which Patients Should Receive Adjuvant Chemotherapy? 
 
Triple-negative breast cancer (TNBC). The Panel recommended adjuvant chemotherapy 
for TNBC stage T1b pN0 and higher; it recommended against routine adjuvant 
chemotherapy for pT1a pN0 TNBC (Table 4). The Panel preferred anthracycline- and 
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taxane-based chemotherapy for most patients, but particularly for those with stage II and 
III disease. The Panel clearly recommended against routine use of platinum-based 
chemotherapy in unselected TNBC cases. In BRCA1/2 associated cancers, the Panel was 
evenly split on whether to recommend adjuvant platinum chemotherapy though agreed 
that such patients should receive alkylating chemotherapy in addition to a taxane and 
anthracycline. Acceptable regimens included dose-dense and non-dose-dense 
anthracycline- , taxane- , and alkylator chemotherapy schedules (Table 5).  
 
HER2 Positive Breast Cancer. The Panel recommended adjuvant chemotherapy and anti-
HER2 therapy for HER2 positive, stage pT1b pN0 and higher breast cancers; it 
recommended against routine adjuvant chemotherapy and anti-HER2 therapy for pT1a 
pN0 HER2 positive breast cancers. The Panel believed that the paclitaxel-trastuzumab 
regimen was sufficient for most stage 1, HER2 positive cancer but recommended anti-
HER2 therapy be paired with additional chemotherapy agents for stage II or III cancers 
(Table 5). 
 
The Panel recommended a duration of one year of adjuvant trastuzumab (Table 5). In 
women who received neoadjuvant anti-HER2 therapy with dual blockade pertuzumab 
and trastuzumab, the Panel recommended completion of one year of trastuzumab alone 
but did not recommend adjuvant pertuzumab based on current evidence, acknowledging 
that data on the role of adjuvant pertuzumab are expected in 2017. 
The Panel endorsed adjuvant use of adequately evaluated biosimilar trastuzumab. 
There is evidence from a single randomized trial that extended adjuvant therapy with 
neratinib after one year of trastuzumab may reduce recurrence in HER2 positive breast 
cancer, particularly in ER positive, HER2 positive cancers. The Panel did not specifically 
address the role of this agent pending further study (Table 5). 
 
ER Positive, HER2 Negative Breast Cancer. Treatment decisions for chemotherapy in ER 
positive breast cancers can be guided by either immunohistochemistry / pathology or by 
gene expression signatures. The Panel identified traditional pathological factors as 
relative indications for adjuvant chemotherapy including node-positive stage, extensive 
lympho-vascular invasion, high Ki-67, and low hormone-receptor expression (Table 6). 
The role of young age, per se, as an indication for chemotherapy was less strongly 
endorsed given the growing appreciation for tumor biology as the determinant of 
outcome and the potential role for ovarian suppression. 
The Panel recommended against adjuvant chemotherapy in women with luminal-B-like 
tumors with low genomic risk scores on the 21-gene and 70-gene signatures when 
presenting with limited nodal involvement [23-25]. In cases of intermediate genomic 
scores or greater, the Panel recommended chemotherapy in luminal-B-like and/or node-
positive cancers. The Panel preferred standard anthracycline- and taxane-based 
chemotherapy for most patients with ER positive breast cancer warranting 
chemotherapy.  
 




The Panel strongly endorsed the use of neoadjuvant therapy for stage II or III, HER2 
positive or triple-negative breast cancer as the preferred initial treatment approach, 
particularly when there is any suggestion that treatment response might enable de-
escalation of surgery or radiotherapy. For HER2 positive cancers, the Panel endorsed dual 
anti-HER2 neoadjuvant therapy with pertuzumab and trastuzumab with chemotherapy as 
a  commonly administered option. For triple-negative cancers, the Panel recommended 
similar approaches to those that would be used in adjuvant therapy (Table 5). 
Patients with residual cancer after neoadjuvant chemotherapy are at greater risk for 
recurrence than those who achieve complete pathological response. At this juncture, 
there are no published data that additional therapy – beyond “standard” treatment – 
reduces recurrence risk in women with residual disease [43]. The Panel was ambivalent 
about the role of additional therapy in the post neoadjuvant setting, and there was no 
consensus on whether additional therapy should routinely be added, nor which treatment 
might be preferred. A recent trial used capecitabine in this setting with very encouraging 
results, but the panelists noted the absence of a published manuscript and, ideally, some 
additional confirmation.  Ongoing clinical trials are evaluating the role of therapeutic 
escalation with various treatments including additional chemotherapies, targeted agents, 
anti-HER2 therapies, PARP inhibitors, and immune checkpoint inhibitors in this setting. 
 
Adjuvant Use of Bone Modifying Therapy  
 
Based on a meta-analysis of multiple trials, the Panel strongly endorsed the use of 
bisphosphonates as adjuvant treatment for postmenopausal women with breast cancer 
[88, 89]. Preferred regimens include zoledronic acid every 6 months for 5 years, or daily 
oral clodronate for 3 years. The Panel recommended against such treatments for 
premenopausal women who are continuing to have regular menstrual cycles. However, a 
majority of the Panel favored this option for premenopausal women receiving ovarian 
function suppression. Denosumab has been shown to reduce bone-health related events 
in breast cancer patients and may reduce recurrence but only a minority of panelists 
favored the option of substituting denosumab for bisphosphonates [44, 45]. 
 
Survivorship and quality of life 
 
The Panel endorsed scalp cooling devices to reduce the likelihood of alopecia related to 
neo/adjuvant chemotherapy with non-anthracycline regimens [46].  
The Panel endorsed lifestyle, diet, and weight management strategies appropriate to the 
general population, acknowledging that there are as yet no data that specific diet, lifestyle 
or weight interventions affect the risk of breast cancer recurrence. 
 
Considerations in Special Populations 
 
Elderly Patients. The Panel resolutely endorsed the statement that there is no absolute 
age limit for adjuvant chemotherapy but rather the recommendation should depend on 
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the health status of the patient, the risk of cancer recurrence, the likely benefit of therapy, 
and patient preferences. The Panel acknowledged that many older patients (greater than 
age 65) with ER positive, HER2 negative, low clinical and/or genomic risk and taking 
adjuvant endocrine therapy could omit radiation therapy after breast conserving surgery, 
particularly those with multiple comorbid health conditions. 
 
Pregnancy After Breast Cancer. There are few data to guide the optimal timing of 
pregnancy after breast cancer, and this is an important area of ongoing research. Given 
the known benefits of adjuvant endocrine therapy, panelists generally favored an 
approach that involved 18 to 24 months of treatment with endocrine before pregnancy, 
and reiterated the importance of resuming endocrine treatment after pregnancy.  
 
Male Breast Cancer. The vast majority of male breast cancers are ER positive. The Panel 
recommended that men with ER positive tumors should receive adjuvant tamoxifen. For 
men with true contraindications to tamoxifen, the Panel believed GnRH agonist therapy 
and an aromatase inhibitor could be an alternative. 
 
Testing for Hereditary Breast Cancer. The Panel endorsed genetic testing for patients with 
strong family history of breast cancer regardless of age; for women diagnosed at age ≤ 40 




The conference endorsed recent trial evidence supporting areas of “escalation” or “de-
escalation” of local and systemic therapies. A large number of treatment 
recommendations are shown although a significant variation in the level of agreement 
was noted. In fact, among more than 200 questions, only a few statements (radiation in 
4 or more positive nodes, distinction between luminal A-like and luminal B-like in order 
to identify important clinical categories) resulted in 100% concordance. The large 
variation in the degrees of support is reflected in the votes recorded in supplementary 
Appendix S1, available at Annals of Oncology online. The Panel recognized that 
recommendations are not intended for all patients, but rather for the majority of them in 
common clinical situations. Fine-tuning of adjuvant therapies for the patient of today 
implies that the available treatments need to be adjusted to the patient’s tumor 
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Table 1. Research recent findings and clinical implications 
 
Field of treatment Findings and implications 
Genetics Multi-gene panel testing for hereditary breast cancer becomes widespread, 
frequently identifying deleterious mutations in women with family history but 
negative BRCA1/2 testing, and also introducing substantial numbers of variants 
of unknown significance [47]. 
Surgery of ductal 
carcinoma in situ 
Meta-analysis and expert panel recommends ≥ 2mm margins as optimal for 
women receiving breast conserving surgery and radiation therapy for DCIS [3]. 
Systemic therapy of 
ductal carcinoma in 
situ (DCIS) 
Randomized trials comparing the aromatase inhibitor, anastrozole, against 
tamoxifen as treatment for estrogen receptor (ER) positive DCIS showed that 
the aromatase inhibitors (AI) was at least as effective as tamoxifen, with 
differences in side effect profiles [4,5]. 
Surgery of the axilla 
after neo-adjuvant 
therapy 
Randomized trials of sentinel node vs axillary node dissection for women with 
node-positive breast cancer following neoadjuvant chemotherapy showed that 
false-negative rates for sentinel lymph node (SLN) were in excess of 10%. 
However, the SLN mapping may be acceptable in selected cohorts [11-13]. 
Partial Breast 
irradiation 
In a randomized trial of low-risk patients with early breast cancer who received 
breast conserving surgery, accelerated partial breast irradiation was not inferior 
to standard whole breast irradiation [48]. 
Regional nodal 
irradiation  
Randomized trials demonstrate reduced local-regional and distant metastatic 
recurrence, with emerging survival advantage, for regional nodal irradiation to 
supraclavicular, axillary and internal mammary lymph nodes when treating high 
risk breast cancers following breast surgery. While reducing risk of recurrence, 
regional nodal irradiation was associated with greater risk of toxicity and may 




The inclusion of carboplatin with anthracycline- and taxane-based 
chemotherapy improved the rate of pathological complete response (pCR) in 
triple negative breast cancer (TNBC) and translated into disease-free survival 
benefit though the role for such treatment when patients additionally receive 
standard alkylator therapy is less clear [49]. In an adaptive randomized trial, the 
addition of carboplatin and the PARP inhibitor, veliparib, improved the rate of 
pCR in TNBC [50]. There were inconsistent findings for the use of nab-paclitaxel 
instead of paclitaxel as neoadjuvant chemotherapy [51, 52].  
Neoadjuvant therapy 
- HER2 targeted 
therapy 
Long term follow up of NeoSphere trial suggests disease-free survival advantage 
parallels increased rate of pCR with pertuzumab- and trastuzumab-based 
therapy [53]. The antibody-drug conjugate, ado-trastuzumab emtansine paired 
with pertuzumab was less effective at achieving pCR than the chemotherapy-
trastuzumab-pertuzumab TCHP [54]. An adaptive randomized trial suggested 
that the dual tyrosine kinase inhibitor neratinib, might improve rates of pCR 
compared to trastuzumab-based regimens though this awaits confirmation 




- endocrine therapy. 
The addition of the cyclin D-cyclin-dependent kinase (CDK) 4/6 inhibitors to 
aromatase inhibitor treatment dramatically suppresses tumor cell proliferation 
[56-58]. Among women with low genomic scores, neoadjuvant endocrine 
therapy is associated with high rates of clinical response [59]. 
Post-neoadjuvant 
therapy - clinical 
trials 
Ongoing trials are evaluating post-neoadjuvant therapy for patients who have 
residual cancer. Agents under investigation include CDK 4/6 inhibitors, poly ADP 
ribose polymerase (PARP) inhibitors, platinum agents, ado-trastuzumab 
emtansine, immunotherapy agents, and others. Adjuvant capecitabine may 
reduce recurrence in women with residual cancer after neoadjuvant 
chemotherapy [43]. 
Adjuvant therapy - 
Chemotherapy 
The ABC trials suggest that inclusion of anthracylines in addition to taxanes and 
alkylator chemotherapy remains valuable for triple-negative and stage II / III ER 
positive cancers treated with adjuvant chemotherapy [60]. The addition of 
bevacizumab to chemotherapy did not improve long term outcomes for triple-
negative breast cancer [61]. Adjuvant capecitabine may reduce recurrence in 
TNBC when added to anthracycline- and taxane- based chemotherapy [62], and 
may reduce recurrence in women with residual cancer after neoadjuvant 
chemotherapy [43]. “Dose-dense” chemotherapy scheduling is validated for 
reducing cancer recurrence while 5-fluorouracil was shown to not affect 
recurrence risk [63, 64].  
Adjuvant therapy - 
HER2 targeted 
therapy 
Despite multiple trials demonstrating enhanced rates of pCR with the addition 
of lapatinib to trastuzumab-based neoadjuvant chemotherapy, long-term 
findings from the ALTTO study do not suggest reduced recurrence risk with 
adjuvant lapatinib [65]. The ExtaNet study suggests that extended anti-HER2 
treatment with the dual tyrosine kinase inhibitor, neratinib, reduces recurrence 
risk, particularly in ER positive, HER2 positive tumors but is associated with 
significant rates of diarrhea [66]. Trastuzumab reduced risk even in small, sub-
centimeter, node-negative breast cancers [67]. Paclitaxel and trastuzumab is an 
effective regimen for stage I breast cancers with low rates of recurrence [68]. 
Preliminary reports suggest that adding pertuzumab to chemotherapy and 
trastuzumab reduces recurrence risk, especially in higher risk, HER2 positive 
breast cancers. 
Adjuvant therapy - 
endocrine therapy 
In premenopausal women with ER positive breast cancer, ovarian suppression 
reduces recurrence in high risk tumors but is associated with more menopausal 
symptoms [32, 69].  In postmenopausal women, multiple trials have studied 
extended endocrine therapy with an aromatase inhibitor and have shown 
reduced rates of breast cancer events, including distant recurrence and 
contralateral breast cancers though the absolute benefit is modest [38, 41]. 
Randomized trials show equivalence between anastrozole and letrozole as 
adjuvant treatment [70].   
Gene Expression 
Profiling for Early 
In the MINDACT trial, a 70-gene signature paired with clinical risk criteria 
identified patients with breast cancer who did not derive substantial benefit 
from adjuvant chemotherapy [23]. In the TAILORx and West German Plan B 
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trials, a very low 21-gene recurrence score identified a cohort of patients with 
ER positive breast cancer and an excellent prognosis with endocrine therapy 
alone [24, 25].  
Bone modifying 
therapy  
A meta-analysis of adjuvant bisphosphonate therapy trials demonstrated 
reduced risk of recurrence in postmenopausal women [44]. Denosumab can 
reduce the risk of bone fracture and may reduce recurrence risk in 
postmenopausal women [45].  
Survivorship  Prospective studies suggest that scalp cooling devices may reduce the incidence 
of alopecia in women with early stage breast cancer receiving non-
anthracycline-based chemotherapy [71, 46]. Interventions including exercise or 
duloxetine may reduce aromatase inhibitor-associated arthralgias [72].  
Metastatic disease – 
immunotherapy 
Anti- Programmed death-1 (PD-1)/Programmed death-ligand 1 (PD-L1) 
antibodies have shown activity as single-agents or in combination with taxane-
based chemotherapy in TNBC [73, 75]. 
Metastatic disease – 
CDK4/6 inhibitors 
Randomized trials have shown that adding CDK4/6 inhibitors to first- or second 
line endocrine therapy improves progression free survival [76-78].  
Metastatic disease – 
HER2 directed 
therapy 
First-line therapy with ado-trastuzumab emtansine and pertuzumab was not 
superior to chemotherapy and trastuzumab or ado-trastuzumab emtansine, 
alone [79]. Adding pertuzumab to second-line chemotherapy in patients not 
previously treated with pertuzumab yielded small clinical benefit [80]. In the 
PERTAIN trial, adding pertuzumab to first-line trastuzumab and endocrine 
therapy improved progression free survival [81].   
Molecular 
mechanisms of 
resistance to therapy 
Activating mutations in the estrogen receptor ESR1 gene arise in 30-40% of 
recurrences on AI therapy and likely account for resistance to AI treatment in 




BRCA mutated tumors show preferential benefit for carboplatin based 
chemotherapy in palliative of metastatic disease [83]. The addition of veliparib 
to carboplatin and paclitaxel chemotherapy did not meaningfully improve 
outcomes in BRCA-associated advanced breast cancer [84]. Preliminary data 
from the Olympia trial suggest that olaparib is a more effective treatment for 
BRCA-associated advanced breast cancer than non-platinum chemotherapy 
options.  




PI3K mutations are common in advanced breast cancer. Randomized trials are 
evaluating the addition of PI3K inhibitors to endocrine therapy. These agents 
vary in their targeting of PI3K isoforms, and the trials differ in their inclusion and 
assessment of tumors by PI3K mutation status. To date, there are no clinically 
compelling outcomes from these studies [85-87]. There may be more activity 




Table 2. Treatment recommendations for loco-regional therapy 
 




Margins Re-excision and 
mastectomies can 
be avoided with 
margins no larger 

















Surgery for DCIS Margins 2 mm margins 







chemotherapy in case 
of downstaging in 
breast and axilla 




and not original 
tumor area 
Resection of the 
original tumor area 
in cases of 
refractory disease 











node biopsy in   
cN (-) at diagnosis 
Appropriate in 
most cases 
Axillary dissection if  




node biopsy in  
cN (+) at diagnosis 
Appropriate only 
if 3 or more lymph 
nodes detected as 
sentinels 
Axillary dissection 
in most cases 
outside of clinical 
trials 
Radiotherapy    
 Hypofractionation Strong 
recommendation 




regimens for all 
others 







breast irradiation  





 Boost Omit boost in 
patients ≥ 60 
years, low grade, 
or favourable 
biological profile  




Consider omit ting 
radiotherapy in 
women with pT1-
pT2, pN1 (1-3) 
and favourable 
biological profile  
PMRT in patients 
with pT3 or four or 
more positive 
lymph nodes 
 Regional nodal 
irradiation (RNI) 
Consider omitting  
RNI in N1 (1-3 
positive lymph 




 RNI in N1 cancers 
and adverse clinical 
features (≤ 40 
years, low or 
negative estrogen 
receptor (ER), G3, 
extensive lympho-
vascular invasion) 








Table 3. Definition of subtypes 
 
 
Molecular subtype according to clinical 
pathological features and to genomic 
score 
Definition 
Ductal Triple negative Negative ER, PgR and HER2 
Basal like breast cancer Genomic assay 
Hormone receptor-negative & HER2-
positive  
ASCO/CAP guidelines 
Hormone receptor-positive & HER2-
positive 
ASCO/CAP guidelines ER and/or PgR 
positive >= 1%1 
HER2-enriched subtype Genomic assay 
  
  
Hormone receptor-positive & HER2-negative – luminal disease as a spectrum 
typically defined by ASCO/CAP guidelines ER and/or PgR positive >= 1%1 
 Luminal like-A subtype : high ER, 
high PgR, low proliferative index2, 
low grade 
The panel agreed that there was no role 
for genomic testing in clinical 
pathological low risk cases (pT1a, pT1b, 
G1, ER high, N0) 
 Luminal A/B like breast cancer  
 Unclassified luminal breast cancer: 
low-intermediate hormone 
receptor, intermediate grade, grey 
zone for proliferative index 
The Panel agreed that genomic classifiers 
are valuable to refine the prognosis for 
node-negative breast cancers.  However, 
it did not uniformly endorse their use for 
prognosis in node-positive breast cancer. 
 Luminal B-like subtype: Low 
receptors, high proliferative index, 
high grade 
Multigene signature “high risk” 
 
 
1 ER values between 1% and 9% were considered equivocal. Thus endocrine therapy alone 
cannot be relied upon for patients with these values. 
2 Ki-67 scores should be interpreted in the light of local laboratory values: as an example, 
if a laboratory has a median Ki-67 score in receptor-positive disease of 20%, values of 30% 








Table 4. Adjuvant systemic treatment recommendations for ER positive/HER2 negative 
early breast cancer. 
 
Subtypes according to 
clinical-pathological and 




ER positive & HER2-negative 
High receptor, low tumour 
burden (pT1a, pT1b), no 
nodal involvement (pN0), 
low proliferation, low 
grade or low “genomic 
risk” 
Endocrine therapy 
alone according to 
menopausal status 
  




beyond 5 years 
No OFS 
 
Postmenopausal Tamoxifen 5 year 
Consider AI as an 
option if tamoxifen is 
contraindicated or not 
tolerated 
No role for 
extended 
adjuvant 
tamoxifen or AI 




of ER and PgR expression, 
intermediate tumour 
burden pT1c, pT2, pN0 or 
pN1 (1-3), intermediate or 















OFS plus tamoxifen or 
OFS plus exemestane 




endocrine therapy with 




Subtypes according to 
clinical-pathological and 






risk” (node positive) 
“intermediate/high 
genomic risk”  






endocrine therapy with 
tamoxifen 
Post-menopausal  












genomic risk” and 
intermediate/high “clinical 
risk” (node positive) 
Chemotherapy 
AI up front 
 
 Extended adjuvant AI 
according to risk and 
tolerability 
Bisphosphonates 
Denosumab has been 
shown to reduce bone-
health related events in 












Table 5. Adjuvant systemic treatment recommendations for triple negative and HER2 
positive early breast cancer. 
 
 
Subtypes according to 
clinical-pathological and 




Ductal triple negative 










































No consensus on post-
neoadjuvant treatment 
in case of residual 
disease, nor which 
treatment might be 
preferred.  
In BRCA1/2 associated 
cancers, the Panel was 




agreed that such 
patients should receive 
alkylating 
chemotherapy.   
ER negative & HER2-positive 
pT1a node negative No systemic therapy No systemic 
therapy  
 













Higher T or N stage Neoadjuvant therapy 
for stage II or III is the 
preferred initial 
treatment approach. 
Patients may be 
treated with TCH 
regimen 
Dual anti-HER2 therapy 
with pertuzumab and 
trastuzumab with 
chemotherapy as the 
31 
 
Subtypes according to 
clinical-pathological and 







continued to 12 
months 
preferred option in the 
neoadjuvant setting  
Data with dual 
blockade in the 
adjuvant setting are 
pending 
Extended adjuvant  
ER positive & HER2-
positive 
As above plus 
endocrine therapy 
appropriate to 
menopausal status  
 Therapy with neratinib 
after one year of 
trastuzumab may 
reduce recurrence in ER 











Table 6. Factors affecting indication to chemotherapy in patients with ER-positive, HER2-
negative disease  
 
Relative Indications for 
chemotherapy in addition to 
endocrine therapy 
Area of uncertainty for 
indication to chemotherapy 
in addition to endocrine 
therapy  
Relative Indications for 
endocrine therapy alone  
Histological Grade 3 
High or intermediate 
“genomic risk”  
Histological Grade 2  
Intermediate “genomic risk” 
Histological Grade 1  
Low “genomic risk” 
High proliferationa  Intermediate proliferationa  Low proliferationa  
Lower ER and PgR level  High/Intermediate degree of 
ER and PgR expression 
Higher ER and PgR level  
Node positive (4 or more 
involved nodes)  
Node positive (1-3 involved 
nodes)  
Node negative  
Presence of extensive 
peritumoral vascular invasion  
 Absence of extensive 
peritumoral vascular invasion  
pT > 5 cm  pT 2.1 – 5 cm  pT  ≤ 2cm  
 
aKi-67 scores should be interpreted in the light of local laboratory values: as an example, 
if a laboratory has a median Ki-67 score in receptor-positive disease of 20%, values of 30% 
or above could be considered clearly high; those of 10% or less clearly low. 
 
 
